Browse result page of B3Pdb
The total number entries retrieved from this search are 65, scroll left/right for detailed information.
| B3pdbIDb3pdb_0292 | PEPTIDE NAMECTAP | PEPTIDE SEQUENCE (1-letter)NA | PEPTIDE SEQUENCE (3-letter)D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTHNA | PEPTIDE CONFORMATIONCyclic | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELAdult Sprague-Dawley rats | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion technique coupled to high performance liquid chromatographic analysis. | In vivo METHODNA | In vivo RESULTT1/2 > 500 min | ACTIONNA | TRANSPORT TYPENA | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEhalf life, serum | RESULTT1/2 > 500 min | LABELNA | PMID 8996221 |
| B3pdbIDb3pdb_0421 | PEPTIDE NAMEVapreotide | PEPTIDE SEQUENCE (1-letter)fCYwKVCW-NH2 | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Tyr-(D)Trp-Lys-Val-Cys-Trp-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys2-Cys7 | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccccc1)CSSC2)Cc3ccc(O)cc3)Cc5c4ccccc4nc5)CCCCN)C(C)C)Cc7c6ccccc6nc7 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEPermeability surface area cofficient | RESULT20.3 µL/(g x min) | LABELDirect iodination | PMID 1975697 |
| B3pdbIDb3pdb_0440 | PEPTIDE NAMEVasoactive intestina | PEPTIDE SEQUENCE (1-letter)HSDAVFTDNYTRLRKQMAVKKYLNSILN | PEPTIDE SEQUENCE (3-letter)His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH28 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,bovine,mouse,rat,porcine | SMILESCCC(C)C(NC(=O)C(CO)NC(=O)C(CC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CC(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(NC(=O)C(CC1=CC=CC=C1)NC(=O)C(NC(=O)C(C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(N)CC1=CN=CN1)C(C)C)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(N)=O)C(N)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.00216 mL/(g x min) | LABELDirect iodination | PMID 12732342 |
| B3pdbIDb3pdb_0459 | PEPTIDE NAMEExendin-4 | PEPTIDE SEQUENCE (1-letter)HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS | PEPTIDE SEQUENCE (3-letter)His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH39 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,bovine,mouse,rat,porcine | SMILESCCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O) NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC (CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(= O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C) C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C (CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C (CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC (=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CN=CN9)N | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEsaturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.01895 mL/(g x min) | LABELDirect iodination | PMID 12629557 |
| B3pdbIDb3pdb_0470 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution vaolume | RESULT0.00137 ml/g | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0471 | PEPTIDE NAMEPhe13,Tyr19-Melanin | PEPTIDE SEQUENCE (1-letter)DFDMLRCMLGRVFRPCWQY | PEPTIDE SEQUENCE (3-letter)Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-Trp-Gln-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys7-Cys16 | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse,rat | SMILES[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.000594 mL/(g x min) | LABELDirect iodination | PMID 10617143 |
| B3pdbIDb3pdb_0484 | PEPTIDE NAMEUrocortin-I | PEPTIDE SEQUENCE (1-letter)DDPPLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2 | PEPTIDE SEQUENCE (3-letter)Asp-Asp-Pro-Pro-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2 | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH40 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEfrog | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.000676 mL/(g x min) | LABELDirect iodination | PMID 11280710 |
| B3pdbIDb3pdb_0491 | PEPTIDE NAMEInsulin | PEPTIDE SEQUENCE (1-letter)A-chain:GIVEQCCTSICSLYQLENYCN B-chain: FVNQHLCGSHLVEALYLVCGERGFFYTPKT | PEPTIDE SEQUENCE (3-letter)A-chain: Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn B-chain:Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys6A-Cys11A, Cys7A-Cys7B, Cys19B-Cys20A | PEPTIDE LENGTH51 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,rat | SMILES[H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N[H])CC2=CC=CC=C2)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[ | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.00086 mL/(g x min) | LABELDirect iodination | PMID 15228601 |
| B3pdbIDb3pdb_0552 | PEPTIDE NAMEMelanocyte-stimulati | PEPTIDE SEQUENCE (1-letter)PLG-NH2 | PEPTIDE SEQUENCE (3-letter)Pro-Leu-Gly-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH3 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,bovine | SMILESCC(C)CC(C(=O)NCC(=O)N)NC(=O)C1CCCN1 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEsaturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.00234 mL/(g x min) | LABELDirect iodination | PMID 8786534 |
| B3pdbIDb3pdb_0553 | PEPTIDE NAMEMelanocyte-stimulati | PEPTIDE SEQUENCE (1-letter)PLG-NH2 | PEPTIDE SEQUENCE (3-letter)Pro-Leu-Gly-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH3 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,bovine | SMILESCC(C)CC(C(=O)NCC(=O)N)NC(=O)C1CCCN1 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution vaolume | RESULT0.0189 ml/g | LABELDirect iodination | PMID 8786534 |
| B3pdbIDb3pdb_0554 | PEPTIDE NAMEMelanocyte-stimulati | PEPTIDE SEQUENCE (1-letter)PLG-NH2 | PEPTIDE SEQUENCE (3-letter)Pro-Leu-Gly-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH3 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,bovine | SMILESCC(C)CC(C(=O)NCC(=O)N)NC(=O)C1CCCN1 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEpermiability constant | RESULT0.00000039 cm/s | LABELDirect iodination | PMID 8786534 |
| B3pdbIDb3pdb_0560 | PEPTIDE NAMETyr-Melanocyte-stimu | PEPTIDE SEQUENCE (1-letter)YPLG | PEPTIDE SEQUENCE (3-letter)Tyr-Pro-Leu-Gly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEbovine | SMILESO=C(NC(C(=O)NCC(=O)O)CC(C)C)C2N(C(=O)C(N)Cc1ccc(O)cc1)CCC2 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEsaturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.00146 mL/(g x min) | LABELH3/C14 | PMID 8769896 |
| B3pdbIDb3pdb_0561 | PEPTIDE NAMETyr-Melanocyte-stimu | PEPTIDE SEQUENCE (1-letter)YPLG | PEPTIDE SEQUENCE (3-letter)Tyr-Pro-Leu-Gly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEbovine | SMILESO=C(NC(C(=O)NCC(=O)O)CC(C)C)C2N(C(=O)C(N)Cc1ccc(O)cc1)CCC2 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEsaturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution vaolume | RESULT0.036 ml/g | LABELH3/C14 | PMID 8769896 |
| B3pdbIDb3pdb_0569 | PEPTIDE NAMETyr-Melanocyte-stimu | PEPTIDE SEQUENCE (1-letter)YPLG | PEPTIDE SEQUENCE (3-letter)Tyr-Pro-Leu-Gly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEbovine | SMILESO=C(NC(C(=O)NCC(=O)O)CC(C)C)C2N(C(=O)C(N)Cc1ccc(O)cc1)CCC2 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIn situ perfusion (single time) | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectonal influx rate constant | RESULT0.00226 mL/(g x min) | LABELH3/C14 | PMID 8769896 |
| B3pdbIDb3pdb_0570 | PEPTIDE NAMETyr-Melanocyte-stimu | PEPTIDE SEQUENCE (1-letter)YPLG | PEPTIDE SEQUENCE (3-letter)Tyr-Pro-Leu-Gly | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH4 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEbovine | SMILESO=C(NC(C(=O)NCC(=O)O)CC(C)C)C2N(C(=O)C(N)Cc1ccc(O)cc1)CCC2 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIn situ perfusion (single time) | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEsaturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEin vitro influx rate | RESULT3.54% | LABELDirect iodination | PMID 11337097 |
| B3pdbIDb3pdb_0575 | PEPTIDE NAMEBiphalin | PEPTIDE SEQUENCE (1-letter)YaGF-NH-NH-FGaY | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Gly-Phe-NH-NH-Phe-Gly-(D)Ala-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEcat | SMILESO=C(N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)NNC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C)Cc2ccccc2)Cc3ccccc3)C)[C@@H](N)Cc4ccc(O)cc4 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.001 mL/(g x min) | LABELDirect iodination | PMID 11714884 |
| B3pdbIDb3pdb_0576 | PEPTIDE NAMEBiphalin | PEPTIDE SEQUENCE (1-letter)YaGF-NH-NH-FGaY | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Gly-Phe-NH-NH-Phe-Gly-(D)Ala-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEcat | SMILESO=C(N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)NNC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C)Cc2ccccc2)Cc3ccccc3)C)[C@@H](N)Cc4ccc(O)cc4 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution vaolume | RESULT0.0097 ml/g | LABELDirect iodination | PMID 11714884 |
| B3pdbIDb3pdb_0584 | PEPTIDE NAMED-Penicillamine-D-Pe | PEPTIDE SEQUENCE (1-letter)Y-Pen-GF-Pen | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Pen-Gly-Phe-(D)Pen | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATION(D)Pen2-(D)Pen5 | PEPTIDE LENGTH5 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman | SMILESO=C(O)[C@@H]2NC(=O)[C@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(SSC2(C)C)(C)C)Cc3ccccc3 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.0022 mL/(g x min) | LABELDirect iodination | PMID 11714884 |
| B3pdbIDb3pdb_0585 | PEPTIDE NAMED-Penicillamine-D-Pe | PEPTIDE SEQUENCE (1-letter)Y-Pen-GF-Pen | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Pen-Gly-Phe-(D)Pen | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATION(D)Pen2-(D)Pen5 | PEPTIDE LENGTH5 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman | SMILESO=C(O)[C@@H]2NC(=O)[C@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(SSC2(C)C)(C)C)Cc3ccccc3 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution vaolume | RESULT0.0143 ml/g | LABELDirect iodination | PMID 11714884 |
| B3pdbIDb3pdb_0594 | PEPTIDE NAMESAM 995 | PEPTIDE SEQUENCE (1-letter)YtGFLS-NH2 | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Thr-Gly-Phe-Leu-Ser-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH6 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(N)Cc1ccc(O)cc1)C(O)C)Cc2ccccc2)CC(C)C)CO | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEsaturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEVolume of donor compartment | RESULT0.1678 ml/g | LABELNA | PMID 1357139 |
| B3pdbIDb3pdb_0609 | PEPTIDE NAMENesfatin-1 | PEPTIDE SEQUENCE (1-letter)VPIDVDKTKVHNVEPVESARIEPPDTGLYYDEYLKQVIEVLETDPHFREKLQKADIEEIRSGRLSQELDLVSHKVRTRLDEL | PEPTIDE SEQUENCE (3-letter)Val-Pro-Ile-Asp-Val-Asp-Lys-Thr-Lys-Val-His-Asn-Val-Glu-Pro-Val-Glu-Ser-Ala-Arg-Ile-Glu-Pro-Pro-Asp-Thr-Gly-Leu-Tyr-Tyr-Asp-Glu-Tyr-Leu-Lys-Gln-Val-Ile-Glu-Val-Leu-Glu-Thr-Asp-Pro-His-Phe-Arg-Glu-Lys-Leu-Gln-Lys-Ala-Asp-Ile-Glu-Glu-Ile-Arg-Ser-Gly-Arg-Leu-Ser-Gln-Glu-Leu-Asp-Leu-Val-Ser-His-Lys-Val-Arg-Thr-Arg-Leu-Asp-Glu-Leu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH82 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDENA | SMILES[H]N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@H](CC(O)=O)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](CCC(O) | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.0003049 mL/(g x min) | LABELDirect iodination | PMID 18006117 |
| B3pdbIDb3pdb_0640 | PEPTIDE NAMEUrocortin II | PEPTIDE SEQUENCE (1-letter)VILSLDVPIGLLRILLEQARYKAARNQAATNAQILAHV | PEPTIDE SEQUENCE (3-letter)Val-Ile-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Leu-Arg-Ile-Leu-Leu-Glu-Gln-Ala-Arg-Tyr-Lys-Ala-Ala-Arg-Asn-Gln-Ala-Ala-Thr-Asn-Ala-Gln-Ile-Leu-Ala-His-Val | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH38 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDErat | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.02021 mL/(g x min) | LABELDirect iodination | PMID 12065889 |
| B3pdbIDb3pdb_0651 | PEPTIDE NAMELuteinizing hormone- | PEPTIDE SEQUENCE (1-letter)Pyr-HWSYGLRPG | PEPTIDE SEQUENCE (3-letter)Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH10 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse | SMILESO=C(NCC(=O)O)[C@H]6N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H]1NC(=O)CC1)Cc2ncnc2)Cc4c3ccccc3nc4)CO)Cc5ccc(O)cc5)CC(C)C)CCCNC(=[N@H])N)CCC6 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEsaturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.01251 mL/(g x min) | LABELDirect iodination | PMID 1887877 |
| B3pdbIDb3pdb_0652 | PEPTIDE NAMELuteinizing hormone- | PEPTIDE SEQUENCE (1-letter)Pyr-HWSYGLRPG | PEPTIDE SEQUENCE (3-letter)Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH10 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEmouse | SMILESO=C(NCC(=O)O)[C@H]6N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H]1NC(=O)CC1)Cc2ncnc2)Cc4c3ccccc3nc4)CO)Cc5ccc(O)cc5)CC(C)C)CCCNC(=[N@H])N)CCC6 | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEsaturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEPermeability surface area cofficient | RESULT0.02 µL/(g x min) | LABELDirect iodination | PMID 1887877 |
| B3pdbIDb3pdb_0658 | PEPTIDE NAMEDes-octanoyl ghrelin | PEPTIDE SEQUENCE (1-letter)GSSFLSPEHQKAQQRKESKKPPAKLQPR | PEPTIDE SEQUENCE (3-letter)Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH28 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.000573 mL/(g x min) | LABELDirect iodination | PMID 12130749 |
| B3pdbIDb3pdb_0659 | PEPTIDE NAMEDes-octanoyl ghrelin | PEPTIDE SEQUENCE (1-letter)GSSFLSPEHQKAQQRKESKKPPAKLQPR | PEPTIDE SEQUENCE (3-letter)Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH28 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution vaolume | RESULT0.011 ml/g | LABELDirect iodination | PMID 12130749 |
| B3pdbIDb3pdb_0667 | PEPTIDE NAMEPeptide YY (3-36) | PEPTIDE SEQUENCE (1-letter)IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY | PEPTIDE SEQUENCE (3-letter)Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH32 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.00234 mL/(g x min) | LABELDirect iodination | PMID 12750431 |
| B3pdbIDb3pdb_0677 | PEPTIDE NAMEJMV 2012 | PEPTIDE SEQUENCE (1-letter)KKPYILKKPYIL | PEPTIDE SEQUENCE (3-letter)Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,mouse,rat | SMILESO=C(NC(C(=O)N1CCCC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3C(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)O)CC(C)C)C(C)CC)Cc2ccc(O)cc2)CCC3)CCCCN)CCCCN)CC(C)C)C(C)CC)Cc4ccc(O)cc4)CCCCN)C(N)CCCCN | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEsaturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.00339 mL/(g x min) | LABELDirect iodination | PMID 8786534 |
| B3pdbIDb3pdb_0678 | PEPTIDE NAMEJMV 2012 | PEPTIDE SEQUENCE (1-letter)KKPYILKKPYIL | PEPTIDE SEQUENCE (3-letter)Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,mouse,rat | SMILESO=C(NC(C(=O)N1CCCC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3C(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)O)CC(C)C)C(C)CC)Cc2ccc(O)cc2)CCC3)CCCCN)CCCCN)CC(C)C)C(C)CC)Cc4ccc(O)cc4)CCCCN)C(N)CCCCN | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution vaolume | RESULT0.0267 ml/g | LABELDirect iodination | PMID 8786534 |
| B3pdbIDb3pdb_0679 | PEPTIDE NAMEJMV 2012 | PEPTIDE SEQUENCE (1-letter)KKPYILKKPYIL | PEPTIDE SEQUENCE (3-letter)Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH12 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,mouse,rat | SMILESO=C(NC(C(=O)N1CCCC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3C(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)O)CC(C)C)C(C)CC)Cc2ccc(O)cc2)CCC3)CCCCN)CCCCN)CC(C)C)C(C)CC)Cc4ccc(O)cc4)CCCCN)C(N)CCCCN | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEpermiability constant | RESULT0.000000565 cm/s | LABELDirect iodination | PMID 8786534 |
| B3pdbIDb3pdb_0684 | PEPTIDE NAMEConnective tissue-ac | PEPTIDE SEQUENCE (1-letter)fCYwRT-Pen-T-NH2 | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Tyr-(D)Trp-Arg-Thr-Pen-Thr-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccccc1)CSSC2(C)C)Cc3ccc(O)cc3)Cc5c4ccccc4nc5)CCCNC(=[N@H])N)C(O)C)C(O)C | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEInitial distribution vaolume | RESULT0.0191 ml/g | LABELH3/C14 | PMID 8996221 |
| B3pdbIDb3pdb_0685 | PEPTIDE NAMEConnective tissue-ac | PEPTIDE SEQUENCE (1-letter)fCYwRT-Pen-T-NH2 | PEPTIDE SEQUENCE (3-letter)(D)Phe-Cys-Tyr-(D)Trp-Arg-Thr-Pen-Thr-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH8 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)C(NC(=O)C2NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)Cc1ccccc1)CSSC2(C)C)Cc3ccc(O)cc3)Cc5c4ccccc4nc5)CCCNC(=[N@H])N)C(O)C)C(O)C | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEnon saturable | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.00161 mL/(g x min) | LABELH3/C14 | PMID 8996221 |
| B3pdbIDb3pdb_0695 | PEPTIDE NAMELSZ 1025 | PEPTIDE SEQUENCE (1-letter)YcGFcSG-NH2 | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Cys-Gly-Phe-(D)Cys-Ser-Gly-NH2 | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATION(D)Cys2-(D)Cys5 | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDErat,porcine | SMILESO=C(N)CNC(=O)[C@H](NC(=O)[C@@H]2NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)CSSC2)Cc3ccccc3)CO | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant,initial | RESULT0.00079 ml/(g x min) | LABELDirect iodination | PMID 11033091 |
| B3pdbIDb3pdb_0697 | PEPTIDE NAMELSZ 1025 | PEPTIDE SEQUENCE (1-letter)YcGFc-(β-D-Glc)SG-NH2 | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Cys-Gly-Phe-(D)Cys-(β-D-Glucose)Ser-Gly-NH2 | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATION(D)Cys2-(D)Cys5 | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)CNC(=O)[C@@H](NC(=O)[C@H]2NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)CSSC2)Cc3ccccc3)CO[C@@H]4OC(CO)[C@H](O)C(O)[C@H]4O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant,initial | RESULT0.00157 ml/(g x min) | LABELDirect iodination | PMID 11033091 |
| B3pdbIDb3pdb_0699 | PEPTIDE NAMELSZ 62 | PEPTIDE SEQUENCE (1-letter)YcGFc-(α-D-Glc)SG-NH2 | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Cys-Gly-Phe-(D)Cys-(α-D-Glucose)Ser-Gly-NH2 | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATION(D)Cys2-(D)Cys5 | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)CNC(=O)[C@@H](NC(=O)[C@H]2NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)CSSC2)Cc3ccccc3)CO[C@H]4OC(CO)[C@H](O)C(O)[C@@H]4O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant,initial | RESULT0.00133 ml/(g x min) | LABELDirect iodination | PMID 11033091 |
| B3pdbIDb3pdb_0701 | PEPTIDE NAMESAM 1025 | PEPTIDE SEQUENCE (1-letter)YcGFc-(β-D-Glc)sG-NH2 | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Cys-Gly-Phe-(D)Cys-(β-D-Glucose) (D)Ser-Gly-NH2 | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATION(D)Cys2-(D)Cys5 | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)CNC(=O)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)CSSC2)Cc3ccccc3)CO[C@@H]4OC(CO)[C@@H](O)C(O)[C@H]4O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant,initial | RESULT0.00057 ml/(g x min) | LABELDirect iodination | PMID 11033091 |
| B3pdbIDb3pdb_0703 | PEPTIDE NAMESAM 1040 | PEPTIDE SEQUENCE (1-letter)YcGFc-(β-D-Xyl)SG-NH2 | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Cys-Gly-Phe-(D)Cys-(β-D-Xylose)Ser-Gly-NH2 | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATION(D)Cys2-(D)Cys5 | PEPTIDE LENGTH7 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(N)CNC(=O)[C@H](NC(=O)[C@@H]2NC(=O)[C@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)CSSC2)Cc3ccccc3)CO[C@@H]4O[C@H](CO)C(O)[C@@H]4O | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant,initial | RESULT0.00133 ml/(g x min) | LABELDirect iodination | PMID 11033091 |
| B3pdbIDb3pdb_0715 | PEPTIDE NAMEGlycylsarcosine | PEPTIDE SEQUENCE (1-letter)G-Sar | PEPTIDE SEQUENCE (3-letter)Gly-Sar | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH2 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman | SMILESO=C(N(C)CC(=O)O)CN | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectional flux rate constant | RESULT0.0076 mL/(g x min) | LABELNA | PMID 30962462 |
| B3pdbIDb3pdb_0720 | PEPTIDE NAME[(D)Ala2,(D)Leu5] En | PEPTIDE SEQUENCE (1-letter)YaGFl | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Gly-Phe-(D)Leu | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH5 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEhuman,porcine | SMILESO=C(O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C)Cc2ccccc2)CC(C)C | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEApparent permiability cofficient | RESULT0.00000005 cm/s | LABELNA | PMID 18855917, 12388672 |
| B3pdbIDb3pdb_0744 | PEPTIDE NAMEDalargin | PEPTIDE SEQUENCE (1-letter)YaGFLR | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Gly-Phe-Leu-Arg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH6 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESO=C(O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C)Cc2ccccc2)CC(C)C)CCCNC(=[N@H])N | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEVolume of donor compartment | RESULT0.0167 ml/g | LABELH3/C14 | PMID 12682214 |
| B3pdbIDb3pdb_0870 | PEPTIDE NAMEAcyloxyalkoxy-based | PEPTIDE SEQUENCE (1-letter)cyclo(YaGFl) linker: -COOCH2O- | PEPTIDE SEQUENCE (3-letter)cyclo(Tyr-(D)-Ala-Gly-Phe-(D)Leu) linker: -COOCH2O- | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH5 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEApparent permiability cofficient | RESULT0.00000012 cm/s | LABELNA | PMID 18855917, 12388672 |
| B3pdbIDb3pdb_0871 | PEPTIDE NAMECoumarinic acid-base | PEPTIDE SEQUENCE (1-letter)cyclo(YaGFl) linker: -COC=C-phenoxy-(coumarinic acid) | PEPTIDE SEQUENCE (3-letter)cyclo(Tyr-(D)-Ala-Gly-Phe-(D)-Leu) linker: -COC=C-phenoxy-(coumarinic acid) | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH5 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEApparent permiability cofficient | RESULT0.00000004 cm/s | LABELNA | PMID 18855917, 12388672 |
| B3pdbIDb3pdb_0872 | PEPTIDE NAMEOxymethyl-modified c | PEPTIDE SEQUENCE (1-letter)cyclo(YaGFl) linker:-COC=C-phenoxy-CH2O- (oxymethyl coumarinic acid) | PEPTIDE SEQUENCE (3-letter)cyclo(Tyr-(D)-Ala-Gly-Phe-(D)-Leu) linker: -COC=C-phenoxy-CH2O- (oxymethyl coumarinic acid) | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH5 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEApparent permiability cofficient | RESULT0.00000007 cm/s | LABELNA | PMID 18855917, 12388672 |
| B3pdbIDb3pdb_0873 | PEPTIDE NAMEDalargin-SS-SynB1 | PEPTIDE SEQUENCE (1-letter)YaGFLR-NHC2H4S-SC2H4NH-RGGRLSYSRRRFSTSTGR-NH2 | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Gly-Phe-Leu-Arg-NHC2H4S-SC2H4NH-Arg-Gly-Gly-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe-Ser-Thr-Ser-Thr-Gly-Arg-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys-Cys (linker) | PEPTIDE LENGTH20 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEVolume of donor compartment | RESULT0.309 ml/g | LABELH3/C14 | PMID 12682214 |
| B3pdbIDb3pdb_0874 | PEPTIDE NAMEDalargin-SS-SynB3 | PEPTIDE SEQUENCE (1-letter)YaGFLR-C2H4S-SC2H4-RRLSYSRRRF-NH2 | PEPTIDE SEQUENCE (3-letter)Tyr-(D)Ala-Gly-Phe-Leu-Arg-NHC2H4S-SC2H4NH-Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe-NH2 | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONCys-Cys (linker) | PEPTIDE LENGTH16 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEVolume of donor compartment | RESULT0.24 ml/g | LABELH3/C14 | PMID 12682214 |
| B3pdbIDb3pdb_0905 | PEPTIDE NAMEAngiopep-7 | PEPTIDE SEQUENCE (1-letter)TFFYGGSRGRRNNFRTEEY | PEPTIDE SEQUENCE (3-letter)Thr-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-Arg-Arg-Asn-Asn-Phe-Arg-Thr-Glu-Glu-Tyr | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH19 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSE% injected dose | RESULT0.22 %/g | LABELDirect iodination | PMID 29090274 |
| B3pdbIDb3pdb_0969 | PEPTIDE NAMEDoxorubicin-SynB1 | PEPTIDE SEQUENCE (1-letter)Doxorubicin-linker-RGGRLSYSRRRFSTSTGR | PEPTIDE SEQUENCE (3-letter)Doxorubicin-linker-Arg-Gly-Gly-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe-Ser-Thr-Ser-Thr-Gly-Arg | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH18 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIn situ perfusion (single time) | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectonal influx rate constant | RESULT0.0684 mL/(g x min) | LABELH3/C14 | PMID 12164379 |
| B3pdbIDb3pdb_0970 | PEPTIDE NAMEDoxorubicin-(D)-Pene | PEPTIDE SEQUENCE (1-letter)Doxorubicin-linker-rqikiwfqnrrmkwkk | PEPTIDE SEQUENCE (3-letter)Doxorubicin-linker-(D)Arg-(D)Gln-(D)Ile-(D)Lys-(D)Ile-(D)Trp-(D)Phe-(D)Gln-(D)Asn-(D)Arg-(D)Arg-(D)Met-(D)Lys-(D)Trp-(D)Lys-(D)Lys | N-TERMINAL MODIFICATION | C-TERMINAL MODIFICATION | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH16 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYin situ brain perfusion | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEVolume of donor compartment | RESULT0.77764 ml/g | LABELH3/C14 | PMID 11123372 |
| B3pdbIDb3pdb_0971 | PEPTIDE NAMEDoxorubicin-(D)-Pene | PEPTIDE SEQUENCE (1-letter)Doxorubicin-linker-rqikiwfqnrrmkwkk | PEPTIDE SEQUENCE (3-letter)Doxorubicin-linker-(D)Arg-(D)Gln-(D)Ile-(D)Lys-(D)Ile-(D)Trp-(D)Phe-(D)Gln-(D)Asn-(D)Arg-(D)Arg-(D)Met-(D)Lys-(D)Trp-(D)Lys-(D)Lys | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH16 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDEChemically synthesized | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIn situ perfusion (single time) | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectonal influx rate constant | RESULT0.072 mL/(g x min) | LABELH3/C14 | PMID 10727512 |
| B3pdbIDb3pdb_0972 | PEPTIDE NAMEDoxorubicin-SynB3 | PEPTIDE SEQUENCE (1-letter)Doxorubicin-linker-RRLSYSRRRF | PEPTIDE SEQUENCE (3-letter)Doxorubicin-linker-Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe | N-TERMINAL MODIFICATIONNA | C-TERMINAL MODIFICATION NA | CHEMICAL MODIFICATIONNA | PEPTIDE LENGTH10 | PEPTIDE CONFORMATIONLinear | PEPTIDE NATURENA | SOURCE/ORIGIN OF PEPTIDE | SMILESNA | CELL LINENA | In vitro CONCENTRATIONNA | In vitro METHODNA | In vitro RESULTNA | ANIMAL MODELNA | In vivo CONCENTRATIONNA | In vivo MODE OF DELIVERYIn situ perfusion (single time) | In vivo METHODNA | In vivo RESULTNA | ACTIONNA | TRANSPORT TYPEPermeability | SUBCELLULAR LOCALISATIONNA | COMBINATIONNA | PHYSICAL CONDITIONNA | RESPONSEUnidirectonal influx rate constant | RESULT0.1386 mL/(g x min) | LABELH3/C14 | PMID 10727512 |